Asparaginase Erwinia Chrysanthemi

Phase 3

Asparaginase Erwinia Chrysanthemi is one of 71 therapeutic programs targeting Acute Lymphoblastic Leukemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Acute Lymphoblastic LeukemiaActive, not recruiting

B Acute Lymphoblastic LeukemiaActive, not recruiting

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRecruiting

Acute Leukemia of Ambiguous LineageRecruiting

Acute Lymphoblastic LeukemiaPreclinical

Active, not recruiting

B Acute Lymphoblastic LeukemiaPhase 3

Active, not recruiting

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativePhase 2

Recruiting

Acute Leukemia of Ambiguous LineagePhase 2

Recruiting

Competition

Competitive Landscape

408 competitors in Acute Lymphoblastic Leukemia

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

40 2

Blincyto

Amgen

Phase 3

45 3

Elspar

DDutch Childhood Oncology Group

Phase 3

47 4

Cerubidine

EEastern Cooperative Oncology Group

Phase 3

43 5

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

44 6

Oncovin

EEastern Cooperative Oncology Group

Phase 3

78 7

Zyloprim

Alnylam Pharmaceuticals

Phase 3

14 8

Iclusig

Takeda

Phase 3

14 9

Medrol

Pfizer

Phase 3

13 10

Neupogen

EEastern Cooperative Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Active, not recruiting

B Acute Lymphoblastic Leukemia

NCT03914625

Q3 2028

Phase 2Recruiting

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

NCT06738368

Q4 2028

Phase 2Recruiting

Acute Leukemia of Ambiguous Lineage

NCT06317662

Q4 2031

PreclinicalActive, not recruiting

Acute Lymphoblastic Leukemia

NCT02553460

Clinical

Trials by Indication[1]

Acute Leukemia of Ambiguous Lineage1 trial

A Phase 2 Study of Blinatumomab in Combination With Chemotherapy for Infants With Newly Diagnosed Acute Lymphoblastic Leukemia With Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06317662·153 enrolled

B Acute Lymphoblastic Leukemia1 trial

A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT03914625·6,720 enrolled

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative1 trial

Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) ± Rituximab + Recombinant Erwinia Asparaginase (JZP458; Rylaze®) for the Treatment of Newly-Diagnosed Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Lymphoma/Leukemia

Recruiting·UUniversity of Washington·Phase 2·NCT06738368·30 enrolled

Acute Lymphoblastic Leukemia1 trial

Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I

Active, not recruiting·SSt. Jude Children's Research Hospital·Preclinical·NCT02553460·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Asparaginase Erwinia Chrysanthemi. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Asparaginase Erwinia Chrysanthemi. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — St. Jude Children's Research Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: SSt. Jude Children's Research Hospital

Asparaginase Erwinia Chrysanthemi

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2028

Q4 2028

Q4 2031

Trials by Indication[1]

Acute Leukemia of Ambiguous Lineage1 trial

B Acute Lymphoblastic Leukemia1 trial

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative1 trial

Acute Lymphoblastic Leukemia1 trial

References

Drug Info

Quick Facts

Related News